Renalytix is focused on addressing the global public health crisis of chronic kidney disease (CKD) through its innovative KidneyIntelX™ technology. This bioprognostic methodology is designed to assess the risk of progressive decline in kidney function in patients with type 2 diabetes and CKD stages 1-3b. By providing a clear risk stratification—categorizing patients as low, moderate, or high risk for CKD progression over the next five years—KidneyIntelX enables clinicians to tailor their treatment strategies effectively. This early identification of risk allows for the allocation of resources and interventions that can significantly improve patient outcomes.

The KidneyIntelX test has received FDA marketing authorization and final Medicare coverage determination, underscoring its clinical relevance and potential impact on patient care. By integrating the insights gained from KidneyIntelX with traditional clinical evaluations, healthcare providers can better manage and slow the progression of kidney disease. Renalytix aims to shift the focus from merely treating kidney disease to promoting kidney health, thereby paving the way for more effective and cost-efficient healthcare solutions in the management of CKD.

United States

Renalytix is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease.COVID-19: Renalytix has entered into a joint venture with the Icahn School of Medicine at Mount Sinai (“Mount Sinai”), Kantaro Biosciences, LLC (“Kantaro”), to develop and scale production of COVID-19 antibody test kits.

Renalytix

Company Details